Without revealing much in the way of new data, TopoTarget A/S enjoyed a 45 percent bounce in its share price during early trading Tuesday, as an analysis of the final top-line results from a registration trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) confirmed the drug exceeded the efficacy level defined by the study's primary endpoint, a minimum objective response rate (ORR) of 20 percent. Read More
Drugmakers with calcitonin salmon products under development for postmenopause osteoporosis (PMO) may have to do a lot more work to get the drugs approved following a joint FDA advisory committee meeting Tuesday. Read More
In the March 3, 2013, online edition of Nature Medicine, scientists from Portola Pharmaceuticals Inc. reported on its PRT064445, a recombinant and "ever so slightly engineered" version of Factor Xa that the company hopes will become a universal antidote to next-generation anti-clotting drugs. Read More
More than 240 million surgeries are performed worldwide each year, yet there is no approved product on the market to prevent the dermal scarring that can frequently occur. Read More
• TauRx Pharmaceuticals Ltd., of Singapore, received an equity investment of $10.5 million from Dundee Corp., of Toronto, to support Phase III trials of LMTX for Alzheimer's disease and behavioral-variant fronto-temporal dementia. Read More
• Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assays. Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco. Read More
• Northwest Biotherapeutics Inc., of Bethesda, Md., said its Phase I/II DCVax-Direct trial for all inoperable solid tumor cancers is planned to start within the next 60 days. Read More
• DSM Pharmaceutical Products, of Parsippany, N.J., the manufacturing and technology business of Royal DSM, inked a three-year master supply agreement with Eisai Inc., of Woodcliff Lake, N.J., for the production of sterile products. Read More
• UCB SA, of Brussels, Belgium, reported results from a Phase III study showing that lacosamide monotherapy met the primary endpoint, with a significantly lower exit rate in adults with partial-onset seizures with or without secondary generalization compared with historical controls. Read More
